Skip to NavigationSkip to content

Zejula

New PARP inhibitor hits UK market, offering distinct advantage

Tesaro’s Zejula has been launched in the UK but availability on the NHS has still not been decided. The PARP inhibitor will be made available through private health insurance based on strong data revealed in recent clinical trials.

The data showed that the drug was able to boost progression-free survival in both patients with the BRCA mutation (BRCA1 or BRCA2) and also in patients who did not display the gene mutation.

Tesaro secures EU approval in specific ovarian cancer population

The European Commission has granted Tesaro’s Zejula (niraparib) marketing approval in Europe, it has emerged.  Zejula is a poly (ADP-ribose) polymerase (PARP)1/2 inhibitor and is indicated as a monotherapy for maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. The drug does not require BRCA mutation or other biomarker testing.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches